SIGN UP or LOGIN
YOUR CART
SUPPORT

Happy Thanksgiving!
Please note that our call center will be closed on Thursday November 24

News coming out of November’s Obesity Week

The opening week of November saw a flood of news regarding progress that has been made in the fight against obesity. Some of the discussions concerned social and economic changes that the gathering of specialists in this area is calling for, and many more items dealt with progress that has been made, and is now on the horizon, for the treatment of obesity.

In 2016 the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) published clinical practice guidelines for medical care of patients with obesity, in which the conclusion was “the objective of care in obesity is to increase health of patients and prevent or treat complications.”

The importance of this whole area cannot be underestimated. Obesity is becoming the #1 cause of morbidity and mortality in the general population. About 42% of the adult population are now categorized as being overweight or obese. This categorization is based on the adoption of the standard of Body Mass Index (BMI) – see more below.

The FDA has now ruled that doctors can classify patients with a BMI greater than or equal to 30 (units of the BMI are mg/kg²) on its own, or 27 if they diagnose at least one comorbidity that is weight-related.

One of the most popular items coming out of ObesityWeek was the strong support for laws against discrimination based on weight, and bullying

University of Connecticut’s Professor Rebecca Puhl, the deputy director of the Rudd Center for Food Policy & Obesity, is quoted in the Medscape Medical News as having said called for “changing harmful narratives about body weight promoted in the mass media, challenging harmful ideals of thinness, educating the public about the complex causes of obesity, and treating weight discrimination as a legitimate form of social injustice. Healthcare professionals are not immune to societal weight bias, and curriculums in medical schools rarely (if ever) address this topic,”

Introducing a new player in weight loss medications

A session presented at ObesityWeek dealt with tirzepatide, which is the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonist that targets diabetes II patients and is now being prescribed for obesity.

In May 2022, Mounjaro (generic name: tirzepatide), was approved by the FDA. It can be prescribed as a weekly subcutaneous injection for glycemic control of patients with type II diabetes based on the SURPASS clinical trials.

In much the same way as was experienced with Ozempic (generic name: semaglutide), one of the side effects was significant weight loss. With tirzepatide, the reduction was fairly uniform across BMI ranges and ages, and number of obesity-related comorbidities in patients classified with a BMI over 30 without type II diabetes.

In June, at the American Diabetes Association 2022 annual meeting, researchers reported “unprecedented” weight loss with tirzepatide in patients without type II diabetes.” This led in October to the FDA granting fast track status to tirzepatide for use as an anti-obesity drug.

Is it worth waiting for or switching to Mounjaro?

There already is a class of drugs that address the same areas as tirzepatide, and that are based on glucagon-like peptide-1 (GLP-1), which is one of the main components of Mounjaro. These drugs, Ozempic (a weekly injection) and Rybelsus (a daily oral medication) also produce substantial benefits in sustainable weight reduction. GLP-1 blocks the production of glucagon, which is also involved in regulating blood sugar, by instructing the liver to release stored glucose. Both of these will cause a lower level in food intake. They can also reduce an appetite for high-fat foods, which carry the double penalty of being high in “bad” cholesterol (which creates increased dangers of cardiovascular disease) as well as producing more calories than their equivalent weight in low-fat foods.

Until it has been approved for use here in Israel so that we are able to compete, Tirzepatide will be available only at the manufacturer’s list price of $974.33 per fill (the amount you pay will largely depend on your prescription drug insurance plan.)  In the meantime, why wait when Ozempic & Rybelsus are ready and waiting from us here at IsraelPharm, at the much more reasonable cost of $350 for a four-dose fill, or a full month’s supply of pills. 

How to understand BMI

The Body Mass Index calculates a ratio of weight to height, using a complex formula that needn’t concern us here. It’s enough to know that providing just these two figures is all that it takes to produce the BMI figure. In the following table we are showing the four categories that are used to determine whether a person qualifies for use of any of the pharmaceutical options:

 

BMI Status
Under 18.5 Underweight
18.5 – 24.9 Normal
25.0 – 26.9 Mild overweight – not eligible for prescribed medication
27.0  – 29.9 Mild overweight – eligible for medication if there is one additional weight-related comorbidity (for example type II diabetes or hypertension)
30.0 – 39.9 Overweight – eligible for medication
40.0 and over Obese – eligible for medication

 

Just visit our website to calculate your BMI and go ahead with an order if you qualify. Fill in the figures of height and weight, and our app will do the calculation right then, and tell you if you qualify. 

Leave a Reply

Your email address will not be published.

Categories

Product categories

Archives